Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Wirth, AK; Wange, L; Vosberg, S; Henrich, KO; Rausch, C; Özdemir, E; Zeller, CM; Richter, D; Feuchtinger, T; Kaller, M; Hermeking, H; Greif, PA; Senft, D; Jurinovic, V; Bahrami, E; Jayavelu, AK; Westermann, F; Mann, M; Enard, W; Herold, T; Jeremias, I.
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance.
Leukemia. 2022; 36(12):2863-2874 Doi: 10.1038/s41375-022-01726-7 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Vosberg Sebastian
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Resistance towards cancer treatment represents a major clinical obstacle, preventing cure of cancer patients. To gain mechanistic insights, we developed a model for acquired resistance to chemotherapy by treating mice carrying patient derived xenografts (PDX) of acute lymphoblastic leukemia with widely-used cytotoxic drugs for 18 consecutive weeks. In two distinct PDX samples, tumors initially responded to treatment, until stable disease and eventually tumor re-growth evolved under therapy, at highly similar kinetics between replicate mice. Notably, replicate tumors developed different mutations in TP53 and individual sets of chromosomal alterations, suggesting independent parallel clonal evolution rather than selection, driven by a combination of stochastic and deterministic processes. Transcriptome and proteome showed shared dysregulations between replicate tumors providing putative targets to overcome resistance. In vivo CRISPR/Cas9 dropout screens in PDX revealed broad dependency on BCL2, BRIP1 and COPS2. Accordingly, venetoclax re-sensitized derivative tumors towards chemotherapy, despite genomic heterogeneity, demonstrating direct translatability of the approach. Hence, despite the presence of multiple resistance-associated genomic alterations, effective rescue treatment for polychemotherapy-resistant tumors can be identified using functional testing in preclinical models.
Find related publications in this database (using NLM MeSH Indexing)
Humans - administration & dosage
Mice - administration & dosage
Animals - administration & dosage
CRISPR-Cas Systems - administration & dosage
Antineoplastic Agents - therapeutic use
Neoplasms - genetics
Disease Models, Animal - administration & dosage
Transcriptome - administration & dosage
Xenograft Model Antitumor Assays - administration & dosage

© Med Uni Graz Impressum